PMC:7417114 / 391-764
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T2 | 52-59 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T5 | 306-313 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T1 | 52-59 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T2 | 138-143 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 12 | 293-301 | Species | denotes | patients | Tax:9606 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T5 | 33-333 | Sentence | denotes | There are numerous protein kinases associated with these processes that can be inhibited by FDA-approved drugs, the repurposing of which presents an alluring option as they have been thoroughly vetted for safety and are more readily available for treatment of patients and testing in clinical trials. |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T10 | 15-19 | UBERON:0000104 | denotes | life |
| T11 | 138-143 | CHEBI:23888;CHEBI:23888 | denotes | drugs |
| T75515 | 15-19 | UBERON:0000104 | denotes | life |
| T86084 | 138-143 | CHEBI:23888;CHEBI:23888 | denotes | drugs |